MIAMI--(BUSINESS WIRE)-- Summit Therapeutics Inc. (NASDAQ: SMMT) today announced a clinical trial collaboration with Pfizer Inc. (NYSE: PFE) to evaluate ivonescimab, a novel, investigational PD-1 / ...
May 12, 2025 8:00 AM ETLineage Cell Therapeutics, Inc. (LCTX) About the OpRegen Phase 1/2a Study The Phase 1/2a study is an open-label, single-arm, multi-center, dose-escalation trial evaluating a ...
NEW ORLEANS, May 1, 2025 /PRNewswire/ -- LongueVue Capital ("LVC") is pleased to announce that its portfolio company, Summit Clinical Research ("Summit" or the "Company"), in partnership with Pinnacle ...
MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced results from the Phase III HARMONi-6 trial, conducted in China and sponsored by our ...
Mean vision gains of +9 letters among patients with extensive coverage of OpRegen cell therapy to the Geographic Atrophy (GA) lesion site Evidence of retinal structural improvement persisted out to 3 ...
Please provide your email address to receive an email when new articles are posted on . LAS VEGAS — In this video, Tarek S. Hassan, MD, professor of ophthalmology at Oakland University William ...
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results